Tvardi Therapeutics, Inc (TVRD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Tvardi Therapeutics, Inc (TVRD) is down 51.2% since the beginning of the year. At $2 per share, TVRD is trading 95.2% below its 52-week high of $44. Investors who bought $1,000 worth of TVRD shares 5 years ago would now be looking at an investment worth $5.

Tvardi Therapeutics, Inc (TVRD) has returned -51.16% so far this year and -91.98% over the past 12 months. Over the last ten years, TVRD has returned -36.85% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.

Based on dividend-adjusted daily data since Jan 31, 2014, TVRD's average daily return is +0.01%, while the average monthly return is -0.22%.

Historically, 48% of months were positive and 52% were negative. The best month was Jul 2015 with a return of +75.4%, while the worst month was Oct 2025 at -88.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, TVRD closed higher 48% of trading days. The best single day was Jul 8, 2026 with a return of +61.3%, while the worst single day was Oct 13, 2025 at -83.9%.

Tvardi Therapeutics, Inc has an annualized alpha of -12.62%, beta of 1.15, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 31, 2014.

• This stock participated in 169.43% of S&P 500 Index downside but only -36.50% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TVRD ranks 12 for risk / return — above 12% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Tvardi Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Tvardi Therapeutics, Inc was 99.86%, occurring on Jun 26, 2026. The portfolio has not yet recovered.

The current Tvardi Therapeutics, Inc drawdown is 99.80%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Tvardi Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Tvardi Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.